# Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

> **NCT01864148** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 419 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** BIIB033
- **OTHER:** Placebo
- **DRUG:** Avonex

## Key facts

- **NCT ID:** NCT01864148
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2017-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864148, "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01864148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*